Northwest Biotherapeutics Reports $26.8 Million Net Loss in Q3 2025

Northwest Biotherapeutics, Inc. reported a net loss of $26.8 million for the third quarter of 2025, compared to a loss of $19.4 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $61.6 million, up from $55.6 million in the prior year. Total revenues for the third quarter were $200,000, a decrease from $357,000 in the same quarter of 2024. The decline in revenue is attributed to reduced research activities and the ongoing costs associated with the company's clinical trials, particularly for its DCVax® product line.

Operating expenses for the third quarter of 2025 were $14.5 million, slightly down from $15.2 million in the previous year. Research and development expenses decreased to $7.5 million from $8.1 million, primarily due to lower manufacturing costs associated with the Specials-Compassionate Treatment program. General and administrative expenses remained relatively stable at $7.1 million compared to $7.0 million in the prior year. The company also reported a significant non-cash loss of $3.3 million related to the change in fair value of derivative liabilities, which was higher than the $1.6 million loss reported in the same quarter of 2024.

In terms of strategic developments, Northwest Biotherapeutics completed the acquisition of Advent BioServices Ltd. on October 24, 2025, which is expected to enhance its manufacturing capabilities for the DCVax products. The acquisition is part of the company's strategy to streamline its operations and reduce costs associated with outsourcing manufacturing. The company has also submitted a Marketing Authorization Application (MAA) for its DCVax®-L product in the U.K., which is currently under review by the Medicines and Healthcare Products Regulatory Agency (MHRA).

As of September 30, 2025, Northwest Biotherapeutics reported total assets of $30.6 million, an increase from $26.7 million at the end of 2024. The company’s cash and cash equivalents rose to $4.6 million from $2.2 million, reflecting a net increase in cash flow from financing activities. However, total liabilities increased to $125.9 million from $105.7 million, primarily due to higher accounts payable and accrued expenses. The company continues to face substantial doubt about its ability to continue as a going concern, as it has not yet established a source of material revenue and relies heavily on external financing to fund its operations.

Looking ahead, Northwest Biotherapeutics anticipates ongoing losses as it continues to invest in research and development, particularly for its DCVax® product line. The company plans to pursue additional financing to support its operations and is exploring potential compassionate use programs in the U.S. The management remains focused on advancing its clinical trials and obtaining regulatory approvals for its products, while also managing its operational costs effectively.